Entrada Therapeutics, Inc.

General ticker "TRDA" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $550.6M (TTM average)

Entrada Therapeutics, Inc. follows the US Stock Market performance with the rate: 36.7%.

Estimated limits based on current volatility of 2.8%: low 8.85$, high 9.36$

Factors to consider:

  • Earnings expected soon, date: 2025-05-06 bmo
  • Current price 22.3% below estimated low

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [11.87$, 22.13$]
  • 2025-12-31 to 2026-12-31 estimated range: [11.73$, 21.81$]

Financial Metrics affecting the TRDA estimates:

  • Positive: 0.87 < Non-GAAP EPS, $ of 1.91
  • Negative: Operating cash flow per share per price, % of -5.52 <= 1.79
  • Negative: Shareholder equity ratio, % of 81.45 > 63.75
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Negative: Industry earnings per price (median), % of -27.42 <= 0
  • Positive: Return on assets ratio (scaled to [-100,100]) of 11.09 > 6.86
  • Negative: Industry operating cash flow per share per price (median), % of -21.10 <= 2.82

Similar symbols

Short-term TRDA quotes

2025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-302025-05-012025-05-0277.588.599.51010.511
Price $

Long-term TRDA plot with estimates

810121416182022Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−0.500.511.5
TRDAS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $0.00MM $129.01MM $210.78MM
Operating Expenses $97.25MM $132.18MM $163.77MM
Operating Income $-97.25MM $-3.16MM $47.01MM
Non-Operating Income $5.26MM $15.22MM $19.47MM
R&D Expense $66.61MM $99.88MM $125.31MM
Income(Loss) $-91.98MM $12.06MM $66.48MM
Taxes $0.00MM $18.74MM $0.86MM
Profit(Loss)* $-87.46MM $-6.68MM $65.63MM
Stockholders Equity $212.55MM $242.36MM $428.68MM
Assets $252.06MM $469.19MM $526.32MM
Operating Cash Flow $-93.79MM $139.80MM $-41.56MM
Capital expenditure $2.89MM $5.61MM $3.16MM
Investing Cash Flow $-148.65MM $-138.40MM $-27.80MM
Financing Cash Flow $0.48MM $21.04MM $102.96MM
Earnings Per Share** $-2.79 $-0.20 $1.76

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.